Levine Oren, Devji Tahira, Xie Feng
a Department of Health Research Methods , Evidence, and Impact, McMaster University , Hamilton , ON , Canada.
b Department of Oncology , McMaster University , Hamilton , ON , Canada.
Hum Vaccin Immunother. 2017 Aug 3;13(8):1765-1767. doi: 10.1080/21645515.2017.1322241. Epub 2017 May 8.
Immune checkpoint inhibitors have revolutionized treatment of advanced cutaneous melanoma. This group of novel therapeutic agents differs from other systemic treatments and has necessitated a new approach for several fundamental aspects of clinical practice in oncology. Marked differences in outcomes associated with immune checkpoint inhibitors compared with other systemic therapies has required a new paradigm for prognostication in the setting of advanced melanoma. Distinct patterns of tumor response have required new norms for disease monitoring. A unique spectrum of toxicity is associated with use of immune checkpoint inhibitors which can be severe and refractory. Patients and clinicians must be informed regarding immune-related adverse events, yet in the published literature, there is substantial variability in reporting. As immune checkpoint inhibitors gain a prominent role in cancer treatment, standardization of adverse event reporting will be vital to ensure validity of evidence and to promote safe clinical practice.
免疫检查点抑制剂彻底改变了晚期皮肤黑色素瘤的治疗方式。这类新型治疗药物与其他全身治疗方法不同，在肿瘤学临床实践的几个基本方面需要采用新的方法。与其他全身治疗相比，免疫检查点抑制剂相关的疗效存在显著差异，这就需要在晚期黑色素瘤的情况下建立新的预后模式。不同的肿瘤反应模式需要新的疾病监测标准。使用免疫检查点抑制剂会伴随一系列独特的毒性，这些毒性可能很严重且难以治疗。必须让患者和临床医生了解免疫相关不良事件，但在已发表的文献中，报告存在很大差异。随着免疫检查点抑制剂在癌症治疗中发挥重要作用，不良事件报告的标准化对于确保证据的有效性和促进安全的临床实践至关重要。
